Vaxcyte, Inc. (NASDAQ:PCVX) Shares Acquired by Nuveen Asset Management LLC

Nuveen Asset Management LLC increased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 14.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 529,650 shares of the company's stock after acquiring an additional 65,713 shares during the quarter. Nuveen Asset Management LLC owned about 0.42% of Vaxcyte worth $43,357,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Wells Fargo & Company MN lifted its holdings in shares of Vaxcyte by 53.7% in the fourth quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock valued at $5,916,000 after purchasing an additional 25,257 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Vaxcyte by 23.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock worth $2,163,000 after purchasing an additional 4,962 shares in the last quarter. TimesSquare Capital Management LLC increased its position in shares of Vaxcyte by 53.7% in the fourth quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock worth $33,860,000 after acquiring an additional 144,516 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in Vaxcyte by 70.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock valued at $49,418,000 after purchasing an additional 246,049 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after acquiring an additional 260 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Needham & Company LLC reiterated a "buy" rating and set a $90.00 target price on shares of Vaxcyte in a research note on Tuesday, April 8th. The Goldman Sachs Group lowered their price objective on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Bank of America reduced their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Cantor Fitzgerald initiated coverage on shares of Vaxcyte in a research note on Tuesday, April 22nd. They set an "overweight" rating on the stock. Finally, Guggenheim restated a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $136.50.

Vaxcyte Stock Down 4.2%

NASDAQ:PCVX traded down $1.41 during trading hours on Friday, hitting $32.54. 1,763,863 shares of the company traded hands, compared to its average volume of 1,371,448. The firm's 50-day simple moving average is $38.53 and its 200-day simple moving average is $68.96. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06. The company has a market cap of $4.20 billion, a PE ratio of -7.07 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the previous year, the company posted ($0.85) earnings per share. As a group, equities research analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Insider Activity

In other news, COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the transaction, the chief operating officer now owns 154,931 shares of the company's stock, valued at $11,351,794.37. This trade represents a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 3.10% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.